GlassScriptPhysician profile
Nathan Henry
NPI 1497370506
$1,555.61
in general payments reported to CMS, 2019-2025
25 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $314 · 2024: $759 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $262.05 | 2023-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $169.50 | 2023-2025 | |
| Lilly USA, LLC | $163.23 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $141.07 | 2024-2025 | Injectafer, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $110.93 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.72 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $92.14 | 2023-2025 | Voquezna |
| Astellas Pharma US INC | $81.10 | 2023-2024 | Veozah |
| Abbvie INC. | $55.90 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.38 | 2024-2025 | Jardiance |
| Noven Therapeutics, LLC | $43.78 | 2024 | Xelstrym |
| Averitas Pharma INC. | $28.71 | 2024 | Qutenza |
| Amgen INC. | $27.39 | 2024-2025 | Repatha, Otezla, Repatha |
| Abiomed | $26.16 | 2025 | |
| Silk Road Medical, INC. | $25.06 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $22.07 | 2025 | Ragwitek, Odactra, Grastek |
| Medtronic, INC. | $18.49 | 2025 | Inceptiv |
| Scilex Pharmaceuticals INC. | $18.07 | 2023 | Ztlido |
| Merck Sharp & Dohme LLC | $17.48 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2025 | |
| Shield Therapeutics INC | $16.39 | 2023 | Accrufer |
| Glaxosmithkline, LLC. | $15.98 | 2023 | Arexvy, Shingrix |
| Agios Pharmaceuticals, INC. | $14.93 | 2024 | |
| Noven Pharmaceuticals, INC. | $14.64 | 2023 | Xelstrym |
| Exact Sciences Corporation | $13.14 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.